There is one clinical trial.
This is a placebo-controlled clinical trial to assess the efficacy and safety of a
combination of lopinavir/ritonavir and Interferon beta-1b in hospitalized patients with MERS.
Primary Outcomes
Measure: 90-day mortality Time: 90-day
Secondary Outcomes
Measure: Organ support-free days (e.g., supplemental O2, ventilator, extracorporeal membrane oxygenation (ECMO), renal replacement and vasopressors) Time: 28 days
Measure: RT-PCR cycle threshold value in the lower respiratory samples Time: At randomization and every 3 days afterwards, until 2 consecutive samples are negative or reaching a maximum of 90 days
Measure: Sequential organ failure assessment (SOFA) scores Time: Days 0, 3, 7, 14, 21 and 28
Measure: ICU-free days Time: Number of days in which patients are not being cared for in the ICU during the first 28 days after enrollment
Measure: Length of stay in hospital Time: Up to one year from enrollment
Measure: Number of Patients with Adverse drug reactions related to the treatment Time: From enrollment to 28 day
Measure: Karnofsky Performance Scale Time: 90-day
Measure: ICU mortality Time: Up to one year from enrollment
Measure: Hospital mortality Time: Up to one year from enrollment
Measure: 28-day mortality Time: 28-day